Last reviewed · How we verify

IV Aminophylline

Damanhour Teaching Hospital · FDA-approved active Small molecule

Aminophylline is a xanthine derivative that inhibits phosphodiesterase enzymes and blocks adenosine receptors, leading to increased intracellular cAMP and bronchodilation.

Aminophylline is a xanthine derivative that inhibits phosphodiesterase enzymes and blocks adenosine receptors, leading to increased intracellular cAMP and bronchodilation. Used for Acute asthma exacerbation, Chronic obstructive pulmonary disease (COPD), Apnea of prematurity.

At a glance

Generic nameIV Aminophylline
Also known asMinophylline-N ampoule
SponsorDamanhour Teaching Hospital
Drug classXanthine bronchodilator
TargetPhosphodiesterase; adenosine receptors
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Aminophylline works primarily by inhibiting phosphodiesterase, which prevents the breakdown of cyclic adenosine monophosphate (cAMP), thereby increasing cAMP levels in smooth muscle cells and promoting relaxation. Additionally, it antagonizes adenosine receptors, which contributes to its bronchodilatory and stimulant effects. These mechanisms make it effective as a bronchodilator and respiratory stimulant, particularly useful in acute asthma exacerbations and apnea of prematurity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: